Pentixapharm raises €20.4M for Phase 3 diagnostic trial
Berlin-based Pentixapharm Holding AG has raised about €20.4 million to fund a pivotal Phase 3 trial of its PET diagnostic PentixaFor and advance its CXCR4-targeted theranostics pipeline.
ADVERTISEMENT
About Georg Kääb
This author has not written his bio yet.
But we are proud to say that Georg Kääb contributed 115 entries already.
Entries by Georg Kääb
Phinomics Brings a New Layer of Cancer Biology from the U.S. to Berlin
U.S. biotech company Phinomics has established its European hub at Bayer Co.Lab Berlin, bringing a research focus that could reshape how scientists understand tumor evolution and drug resistance. The focus is on extrachromosomal DNA rings.
Samsung Targets Swiss CDMO PolyPeptide in $1.8 Billion Deal
Consolidation in the contract development and manufacturing organization (CDMO) sector continues to accelerate. With a bid valued at approximately US$1.8 billion for Swiss peptide specialist PolyPeptide, Samsung Biologics aims to strengthen its position in the fast-growing market for complex biopharmaceuticals.
Bayer rebuilds pharma while waiting for Monsanto relief
A stronger pipeline and new financing give Bayer room to manoeuvre — but investors are still watching one issue: the US glyphosate litigation.
WuXi AppTec bets on expansion in Europe
Global science, local innovation: In an interview with European Biotech Magazine, WuXi AppTec Co-CEO Steve Yang explains why Europe remains a key source of scientific innovation, why the company continues to expand its Munich site despite geopolitical tensions, and why trust, quality, and international collaboration are essential for the future of drug discovery.
Targeted Protein Degradation: Designed to destroy
Targeted protein degradation (TPD) has moved from a highly experimental concept to one of the most closely watched modalities in biopharma. What began with first-generation PROTACs (proteolysis-targeting chimeras) has evolved into a broader “induced proximity” field that now includes molecular glue degraders, degrader-antibody conjugates (DACs), lysosome-targeting chimeras (LYTACs), RNA degraders and other proximity-based therapeutics.
Funding: HMNC and the Long Road to Precision Psychiatry
With a first $50 million tranche of its Series B financing and a commercial partnership with MEDICE, HMNC Brain Health has secured fresh capital for its depression programmes. The deal marks an important milestone for the Munich-based company – nearly a decade after it first set out to transform psychiatry through precision medicine.
Heidelberg-based Veraxa ventures onto Nasdaq in turbulent market environment
Veraxa Biotech, an oncology company spun out of research at the European Molecular Biology Laboratory (EMBL), has completed its merger with SPAC company Voyager Acquisition Corp. and will be trading as of today on the Nasdaq under the ticker symbol VRXA. For the company, which has roots in the Heidelberg region, the move marks its transition from a research-driven company to a publicly listed biotech developer.
Lilly and Boehringer pause $2bn German investments over planned drug-spending curbs
The announcements came almost simultaneously and send a clear signal to policymakers and the industry: both US pharmaceutical group Eli Lilly and German-based Boehringer Ingelheim are calling planned investments in Germany into question, citing the country’s healthcare policy framework.
A fresh start for Molecular Health: technology core becomes start-up Lucera
A restart from within: Molecular Health is becoming Lucera. After years of shifting corporate fortunes, a substantial part of Heidelberg-based Molecular Health is continuing in a new form. An investor consortium has acquired the company’s pharma technology business and relaunched it as Lucera GmbH. Dr Friedrich von Bohlen remains at the helm, while Dr Stephan Brock, the mind behind the Dataome data engine, also stays on board as CTO.